Wells Fargo & Company Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Sciences (NASDAQ:GILD) had its target price boosted by equities researchers at Wells Fargo & Company from $105.00 to $120.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 15.29% from the company’s current price.

GILD has been the subject of a number of other reports. Barclays increased their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Cantor Fitzgerald restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.70.

Gilead Sciences Trading Up 8.3 %

NASDAQ GILD traded up $7.95 during trading hours on Wednesday, reaching $104.09. The company’s stock had a trading volume of 4,736,709 shares, compared to its average volume of 6,879,854. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $104.71. The stock has a market cap of $129.72 billion, a P/E ratio of 1,153.78, a P/E/G ratio of 1.25 and a beta of 0.18. The firm has a fifty day simple moving average of $93.14 and a 200-day simple moving average of $87.12.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Equities analysts forecast that Gilead Sciences will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now owns 8,920 shares of the company’s stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 572,824 shares of company stock valued at $53,611,715. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Slagle Financial LLC grew its position in shares of Gilead Sciences by 4.1% in the 4th quarter. Slagle Financial LLC now owns 28,124 shares of the biopharmaceutical company’s stock worth $2,598,000 after buying an additional 1,100 shares during the last quarter. denkapparat Operations GmbH purchased a new stake in Gilead Sciences in the fourth quarter worth $1,142,000. Premier Fund Managers Ltd boosted its holdings in Gilead Sciences by 46.7% in the fourth quarter. Premier Fund Managers Ltd now owns 15,710 shares of the biopharmaceutical company’s stock valued at $1,445,000 after acquiring an additional 5,000 shares in the last quarter. Orion Portfolio Solutions LLC increased its position in Gilead Sciences by 3.7% during the 4th quarter. Orion Portfolio Solutions LLC now owns 90,026 shares of the biopharmaceutical company’s stock valued at $8,316,000 after purchasing an additional 3,224 shares during the period. Finally, New Age Alpha Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth $10,778,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.